At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Fatima Cardoso, MD, from Champalimaud Cancer Centre, Lisbon, Portugal, discusses the implementation of ESMO guidelines on the treatment of metastatic HER2-positive breast cancer in a case study presentation, including the use of the antibody-drug conjugate, T-DM1, and the anti-HER2 antibody, pertuzumab, in different settings of treatment.
ESMO Clinical Practice Guidelines: Breast cancer case presentation
5 Feb 2016
Oncology
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given